Pascal Brenneisen

Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.

Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom.

Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

KBL Healthcare Ventures (KBL Healthcare) is a venture capital firm founded in 1991 by Zachary C. Berk and Marlene R. Krauss. The firm is headquartered in New York.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Helmholtz-Gemeinschaft Deutscher Forschungszentren eV operates as a scientific research organization. It performs cutting-edge research which contributes substantially to solving the grand challenges of science, society, and industry. The firm focuses on six research fields: Energy, Earth and Environment, Health, Key Technologies, Structure of Matter plus Aeronautics, Space, and Transport. It develops research programs for each of these fields. The company was founded in 1995 and is headquartered in Berlin, Germany.

Man Investments (CH) AG (Man Investments) is the Switzerland-based asset management subsidiary of Man Strategic Holdings Plc, itself a subsidiary of Man Group Plc (LSE: EMG) in Great Britain. Established in 1994, the firm is dedicated solely to alternative investing, offering investors access to a wide range of hedge fund portfolios that target strong, stable capital growth through the market cycle. In 2009 Man Group launched a new investment management business uniting Man's scale and expertise in hedge fund investing with the strengths of RMF Investment Management 's infrastructure and disciplined investment process and Glenwood Capital Investments' proven bottom-up manager selection philosophy. Headquartered in Pfaffikon, Man Investments provides transparent access to hedge fund investing through fund of fund portfolios and customized solutions for institutional and private investors.

The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA.

Carnegie Endowment for International Peace engages in the analysis and development of policy ideas and engagement and collaboration with decision makers in the government, business, and civil society. It refers to issues such as climate and energy, defense and security, democracy and governance, economy, foreign polocy, global governance, nuclear weapons, political reform, society and culture, and technology. The company was founded by Andrew Carnegie in 1910 and is headquartered in Washington, DC.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

The Peres Center for Peace is a non-profit, non-political, non-governmental organization focused on developing and implementing cutting edge peacebuilding programs in innovation, peace education, medicine, business, and environment. It services include training to doctors, peace education, sports, culture and the arts and technology programs. The company was founded by Shimon Peres in 1996 and is headquartered in Tel Aviv-Jaffa, Israel.

Part of XBiotech, Inc., XBiotech USA, Inc. is a company that manufactures antibodies. The company is based in Austin, TX. The company was founded in 2005. The CEO is John Simard.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

HeiQ Materials AG develops and manufactures antimicrobial silver and other sustainable textile effects. It offers textile brands innovation research and development, customized chemical manufacturing, and ingredient branding in one. The company was founded by Carlo Centonze and Murray Height in 2005 and is headquartered in Schlieren, Switzerland.

Credit Suisse Entrepreneur Capital AG (formerly SVC AG für KMU Risikokapital) provides venture capital services for Swiss small and medium enterprises. The company invests in existing businesses, start-up businesses and small-scale businesses. It was founded in 2010 and is headquartered in Zurich, Switzerland.

Swiss Biotech Association operates as an industry association. The private company is based in Zurich, Switzerland. Michael Altorfer has been the CEO of the Swiss company since 2018.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland.

mPharma Health Nigeria Ltd. engages in the development of a pharmaceutical data management platform. The company was founded by Gregory Rockson, Dan Shoukimas and James Finucane in 2013 and is headquartered in Accra, Ghana.

mPharma Data, Inc. engages in the development of an application that enables physicians to prescribe and locate medicines for patients. The company is headquartered in Lexington, MA.

Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Aptissen SA is a Swiss company that focuses on researching, developing, and commercializing medical devices that are based on biopolymers.

Eclipse Bioinnovations, Inc. is a private biotechnology company that develops first-in-class technologies to accelerate the development of RNA genomics discoveries and medicines. The company is based in San Diego, CA. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Laboratory at UC San Diego. Eclipse Bio is an RNA next-generation sequencing (NGS) company founded in 2017 based on technologies and algorithms developed in Dr. The company was founded by Alexander Shishkin, Peter Chu, and Eugene W. Yeo. Peter Chu has been the CEO since incorporation.

Bottmedical AG is a Swiss company that produces CINNA & Naturaligner, which are the world's first antibacterial braces. The private company is based in Basel, Switzerland. These braces correct, protect, and retain teeth while continuously supporting oral hygiene. The company was founded in 2019 by Pascal Brenneisen, Tino Töpper, Jeannette von Jackowski, Bert Müller, Bekim Osmani, Guido Sigron, Tobias Hollritt. Tino Töpper has been the CEO since 2019.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.